miRagen begins Phase I trial for MRG-106 to treat cutaneous T-cell lymphoma

US-based miRagen Therapeutics has started a Phase I trial of its anti-cancer product candidate MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, to treat patients with lymphoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news